Pharmafile Logo

oral treatment

- PMLiVE

Eli Lilly names Ilya Yuffa as executive vice president and president, Lilly Global Markets

Patrik Jonsson, executive vice president and president, Lilly International, will retire at the end of 2026

- PMLiVE

Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients

Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes

- PMLiVE

Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal

The deal focuses on addressing critical unmet medical needs

- PMLiVE

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

The acquisition is to advance treatments for serious autoimmune and allergic diseases

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

- PMLiVE

US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia

The treatment is to protect children under two years of age from respiratory syncytial virus

- PMLiVE

Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer

Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

- PMLiVE

Lilly to acquire AtaiBeckley in deal worth $2.8bn

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

AstraZeneca’s Baxfendy approved by US FDA for adults with uncontrolled hypertension

Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies

- PMLiVE

US FDA approves Taiho’s Inqovi for older adults with acute myeloid leukaemia

In 2026, an estimated 22,720 people in the US will be diagnosed with AML

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links